Person:
YAKUT, NURHAYAT

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

YAKUT

First Name

NURHAYAT

Name

Filters

2016 - 201912020 - 20223
Reset filters

Settings

Author: ERDEM ERALP, ELA ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    COVID-19 disease characteristics in different pediatric age groups
    (2022-01-01) ŞENYÜREK, BETÜL; BORAN, PERRAN; KEPENEKLİ KADAYİFCİ, EDA; YAKUT, NURHAYAT; KARAHASAN, AYŞEGÜL; AYDINER, ELİF; MEMİŞOĞLU, ASLI; GÖKDEMİR, YASEMİN; ERDEM ERALP, ELA; KARADAĞ, BÜLENT TANER; KEPENEKLİ KADAYİFCİ E., YAKUT N., Ergenc Z., Aydiner O., Sarinoglu R. C., KARAHASAN A., Karakoc-Aydiner E., MEMİŞOĞLU A., GÖKDEMİR Y., ERDEM ERALP E., et al.
    Introduction: Little is known about the COVID-19 disease characteristics and differences between different pediatric age groups. This study aimed to investigate the disease characteristics according to age groups. Methodology: We conducted a retrospective, single-center study of pediatric COVID-19 in a tertiary care hospital in Turkey. The patients were divided into three groups: 15 days-24 months old (Group 1), 25-144 months old (Group 2), and 145-210 months old (Group 3) according to age. Results: A total of 139 pediatric patients with COVID-19 were examined. Twenty-nine patients (20.9%) were in Group 1, 52 (37.4%) were in Group 2, 58 (41.7%) were in Group 3. Thirty-nine patients (28.1%) were hospitalized. The most common symptoms were cough (55.4%) and fever (51.8%). The median chest X-ray (CXR) score of hospitalized patients was 1 (min 0-max 7), and the median CXR score of outpatients was 1 (min 0-max 6). Fever was significantly more frequent in Group 1, and chest pain was more frequent in Group 3. Group 1 had significantly higher WBC, lymphocyte, thrombocyte counts, AST, LDH, D-dimer, and Troponin T levels but lower hemoglobin, total protein, and albumin levels. The treatment included antibiotics, oseltamivir, hydroxychloroquine, and supportive therapy. Only one patient (0.7%) received noninvasive mechanical ventilatory support. Conclusions: As we know the clinical course of COVID-19 in children is less severe than in adults. We also found significant differences in both clinical and laboratory findings between different pediatric age groups which supports the theory that disease pathogenesis is highly variable according to age.
  • Thumbnail Image
    PublicationOpen Access
    Successful treatment of allergic bronchopulmonary aspergillosis with posaconazole in a child with cystic fibrosis: Case report and review of the literature
    (2020) ERDEM ERALP, ELA; Yakut, Nurhayat; Kadayifci, EdaKepenekli; Eralp, ElaErdem; Gokdemir, Yasemin
  • Thumbnail Image
    PublicationOpen Access
    Neurologic Adverse Events Associated with Voriconazole Therapy: Report of Two Pediatric Cases
    (HINDAWI LTD, 2016) ERDEM ERALP, ELA; Demir, Sevliya Ocal; Atici, Serkan; Akkoc, Gulsen; Yakut, Nurhayat; Ikizoglu, Nilay Bas; Eralp, Ela Erdem; Soysal, Ahmet; Bakir, Mustafa
    Although voriconazole, a triazole antifungal, is a safe drug, treatment with this agent is associated with certain adverse events such as hepatic, neurologic, and visual disturbances. The current report presents two cases, one a 9-year-old boy and the other a 17-year-old girl, who experienced neurologic side effects associated with voriconazole therapy. Our aim is to remind readers of the side effects of voriconazole therapy in order to prevent unnecessary investigations especially for psychological and ophthalmologic problems. The first case was a 9-year-old boy with cystic fibrosis and invasive aspergillosis that developed photophobia, altered color sensation, and fearful visual hallucination. The second case was a 17-year-old girl with cystic fibrosis and allergic bronchopulmonary aspergillosis, and she experienced photophobia, fatigue, impaired concentration, and insomnia, when the dose of voriconazole therapy was increased from 12mg/kg/day to 16mg/kg/day. The complaints of the two patients disappeared after discontinuation of voriconazole therapy. Our experience in these patients reminded us of the importance of being aware of the neurologic adverse events associated with voriconazole therapy in establishing early diagnosis and initiating prompt treatment. In addition, although serum voriconazole concentration was not measured in the present cases, therapeutic drug monitoring for voriconazole seems to be critically important in preventing neurologic side effects in pediatric patients.
  • Thumbnail Image
    PublicationOpen Access
    Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey
    (FRONTIERS MEDIA SA, 2021-05-07) KARADAĞ, BÜLENT TANER; Karbuz, Adem; Akkoc, Gulsen; Bedir Demirdag, Tugba; Yilmaz Ciftdogan, Dilek; Ozer, Arife; Cakir, Deniz; Hancerli Torun, Selda; Kepenekli, Eda; Erat, Tugba; Dalgic, Nazan; Ilbay, Sare; Karaaslan, Ayse; Erdeniz, Emine H.; Aygun, F. Deniz; Bozdemir, S. Elmas; Hatipoglu, Nevin; Emiroglu, Melike; Sahbudak Bal, Zumrut; Ciftci, Ergin; Bayhan, Gulsum Iclal; Gayretli Aydin, Zeynep Gokce; Ocal Demir, Sevliya; Kilic, Omer; Hacimustafaoglu, Mustafa; Sener Okur, Dicle; Sen, Semra; Yahsi, Aysun; Akturk, Hacer; Cetin, Benhur; Sutcu, Murat; Kara, Manolya; Uygun, Hatice; Tural Kara, Tugce; Korukluoglu, Gulay; Akgun, Ozlem; ustundag, Gulnihan; Demir Mis, Mevsim; Sali, Enes; Kaba, Ozge; Yakut, Nurhayat; Kilic, Orhan; Kanik, M. Kemal; Cetin, Ceren; Dursun, Adem; Cicek, Muharrem; Kockuzu, Esra; Sevketoglu, Esra; Alkan, Gulsum; Guner Ozenen, Gizem; Ince, Erdal; Baydar, Zekiye; Ozkaya, Ahmet Kagan; Ovali, Husnu Fahri; Tekeli, Seher; Celebi, Solmaz; Cubukcu, Birgul; Bal, Alkan; Khalilova, Fidan; Kose, Mehmet; Hatipoglu, Halil Ugur; Dalkiran, Tahir; Turgut, Mehmet; Basak Altas, Ayse; Selcuk Duru, Hatice Nilgun; Aksay, Ahu; Saglam, Sevcan; Sari Yanartas, Mehpare; Ergenc, Zeynep; Akin, Yasemin; Duzenli Kar, Yeter; Sahin, Sabit; Tuteroz, Sadiye Kubra; Bilen, Nimet Melis; Ozdemir, Halil; Senoglu, Mine Cidem; Pariltan Kucukalioglu, Burcu; Besli, Gulser Esen; Kara, Yalcin; Turan, Cansu; Selbest Demirtas, Burcu; Celikyurt, Aydin; Cosgun, Yasemin; Elevli, Murat; Sahin, Aslihan; Bahtiyar Oguz, Serife; Somer, Ayper; Karadag, Bulent; Demirhan, Recep; Turk Dagi, Hatice; Kurugol, Zafer; Taskin, Esra Cakmak; Sahiner, Aysegul; Yesil, Edanur; Ekemen Keles, Yildiz; Sarikaya, Remzi; Erdem Eralp, Ela; Ozkinay, Ferda; Konca, Hatice Kubra; Yilmaz, Songul; Gokdemir, Yasemin; Arga, Gul; Ozen, Seval; Coksuer, Fevziye; Vatansever, Goksel; Tezer, Hasan; Kara, Ates
    Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children. Methods: A retrospective study was conducted by pediatric infectious disease specialists from 32 different hospitals from all over Turkey by case record forms. Pediatric cases who were diagnosed as COVID-19 between March 16, 2020, and June 15, 2020 were included. Case characteristics including age, sex, dates of disease onset and diagnosis, family, and contact information were recorded. Clinical data, including the duration and severity of symptoms, were also collected. Laboratory parameters like biochemical tests and complete blood count, chest X-ray, and chest computed tomography (CT) were determined. Results: There were 1,156 confirmed pediatric COVID-19 cases. In total, male cases constituted 50.3% (n = 582) and females constituted 49.7% (n = 574). The median age of the confirmed cases was 10.75 years (4.5-14.6). Of the total cases, 90 were younger than 1 year of age (7.8%), 108 were 1-3 years of age (9.3%), 148 were 3-6 years of age (12.8%), 298 were 6-12 years of age (25.8%), 233 were 12-15 years of age (20.2%), and 268 cases were older than 15 years of age (23.2%). The most common symptom of the patients at the first visit was fever (50.4%) (n = 583) for a median of 2 days (IQR: 1-3 days). Fever was median at 38.4 degrees C (38.0-38.7 degrees C). The second most common symptom was cough (n = 543, 46.9%). The other common symptoms were sore throat (n = 143, 12.4%), myalgia (n = 141, 12.2%), dyspnea (n = 118, 10.2%), diarrhea (n = 112, 9.7%), stomachache (n = 71, 6.1%), and nasal discharge (n = 63, 5.4%). When patients were classified according to disease severity, 263 (22.7%) patients were asymptomatic, 668 (57.7%) patients had mild disease, 209 (18.1%) had moderate disease, and 16 (1.5%) cases had severe disease. One hundred and forty-nine (12.9%) cases had underlying diseases among the total cases; 56% of the patients who had severe disease had an underlying condition (p < 0.01). The need for hospitalization did not differ between patients who had an underlying condition and those who do not have (p = 0.38), but the need for intensive care was higher in patients who had an underlying condition (p < 0.01). Forty-seven (31.5%) of the cases having underlying conditions had asthma or lung disease (38 of them had asthma). Conclusions: To the best of our knowledge, this is one of the largest pediatric data about confirmed COVID-19 cases. Children from all ages appear to be susceptible to COVID-19, and there is a significant difference in symptomatology and laboratory findings by means of age distribution.